Free Trial
Jack Allen

Jack Allen Analyst Performance

Senior Research Analyst at Robert W. Baird

Jack Allen is a stock analyst at Robert W. Baird focused in the medical sector, covering 4 publicly traded companies. Over the past year, Jack Allen has issued 4 stock ratings, including buy and hold recommendations. While full access to Jack Allen's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jack Allen's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
4 Last 0 Years
Buy Recommendations
75.00% 3 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy75.0%3 ratings
Hold25.0%1 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Jack Allen at Robert W. Baird, the majority (75.0%) have been Buy recommendations, followed by 25.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
4 companies

Jack Allen, an analyst at Robert W. Baird, currently covers 4 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
3 companies
75.0%
Manufacturing
1 company
25.0%

Jack Allen of Robert W. Baird specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
50.0%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
1 company
25.0%
MED - GENERIC DRG
1 company
25.0%

About Jack Allen

Jack Allen is a Baird Senior Research Analyst covering Biotechnology. Prior to joining Baird in 2018, he was a Senior Research Analyst at Informa, working on the Datamonitor Healthcare and Biomedtracker products. Jack received a BS in Chemistry and Economics from Bates College.
Follow on LinkedIn

Jack Allen's Ratings History at Robert W. Baird

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
10/15/2025Upgrade$30.81$64.00Outperform
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
10/2/2025Boost Price Target$4.72$12.00Outperform
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
5/14/2025Lower Price Target$1.13$9.00Outperform
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
5/14/2025Lower Price Target$1.00$4.00Neutral